SCNI Stock Analysis: Buy, Sell, or Hold?
SCNI - Scinai Immunotherapeutics Ltd. American Depositary Shares
$0.32
-0.02 (-4.60%)
▼
5d:
-1.11%
30d:
-36.73%
90d:
-54.4%
HOLD
MODERATE Confidence
Analysis Updated: Jun 18, 2026 12:00 AM ET
Earnings: Jul 01, 2026
10d
Get Alerted When SCNI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: SCNI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: SCNI shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: SCNI is currently trading at $0.32, which is considered oversold relative to its 30-day fair value range of $0.37 to $0.52.
Technical Outlook: Technically, SCNI is in a strong downtrend. The price is currently testing key support at $0.34. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: SCNI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $700.00 (+217629.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, SCNI is in a strong downtrend. The price is currently testing key support at $0.34. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: SCNI has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. Wall Street analysts see significant upside, with an average price target of $700.00 (+217629.4%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.37 -
$0.52
Company Quality Score
40/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
52.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 217629.4% below Wall St target ($700.00)
Trading Range Analysis
30-Day Trading Range
$0.37 -
$0.52
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.34
Resistance Level
$0.50
Current Trend
Strong Downtrend
Technical data as of
Jun 9, 2026
Fundamental Context
Wall Street Target
$700.00
(+217629.4%)
Revenue Growth (YoY)
26.5%
Earnings Growth (YoY)
87.2%
Profit Margin
-261.4%
Share & Embed Analysis
Last updated: June 20, 2026 6:40 AM ET
Data refreshes hourly during market hours. Next update: 7:40 AM
Data refreshes hourly during market hours. Next update: 7:40 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SCNI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NTLA
Intellia Therapeutics Inc |
STRONG BUY
29 analysts |
$27 | 60 BUY |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$412 | 51 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$198 | 58 HOLD |
|
ARGX
argenx NV ADR |
STRONG BUY
22 analysts |
$1029 | 56 HOLD |
|
ACLX
Arcellx Inc |
STRONG BUY
18 analysts |
$113 | 57 HOLD |